{
    "clinical_study": {
        "@rank": "90645", 
        "arm_group": [
            {
                "arm_group_label": "midazolam/propofol injection", 
                "arm_group_type": "Experimental", 
                "description": "Intermittent midazolam/propofol injection controlled by endoscopist"
            }, 
            {
                "arm_group_label": "propofol infusion", 
                "arm_group_type": "Active Comparator", 
                "description": "Continuous propofol infusion with opioid administration"
            }
        ], 
        "brief_summary": {
            "textblock": "Although proper sedation is mandatory for endoscopic procedures such as endoscopic\n      submucosal dissection, the effects of sedation on ESD performance and complications have not\n      been fully evaluated. In the investigators previous retrospective study, en bloc resection\n      and complete resection rates, and procedure time could be improved by sedation with\n      continuous propofol infusion with opioid administration by anesthesiologists. However, there\n      are several limitations to the study including retrospective design. The investigators aimed\n      to evaluate the relationship among sedation methods, satisfaction of endoscopists or\n      patients, clinical outcomes, and complications after endoscopic submucosal dissection for\n      gastric neoplasia."
        }, 
        "brief_title": "Performance of Endoscopic Submucosal Dissection According to the Sedation Method", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Early Gastric Cancer", 
            "Gastric Adenoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenoma", 
                "Stomach Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age, between 20 and 80\n\n          2. Early gastric cancer or adenoma, which is indicated by endoscopic submucosal\n             dissection\n\n          3. ECOG performance status 0 or 1\n\n          4. American Society of Anesthesiologist Physical Status 1, 2, or 3\n\n        Exclusion Criteria:\n\n          1. Previous subtotal gastrectomy\n\n          2. Previous gastrostomy\n\n          3. Repeated endoscopic submucosal dissection\n\n          4. Three or more synchronous lesions\n\n          5. Allergy to midazolam, propofol, fentanyl, or remifentanil\n\n          6. Pregnancy or breast milk feeding\n\n          7. Active infection\n\n          8. Significant cardiopulmonary disease\n\n          9. Active hepatitis or severe hepatic dysfunction\n\n         10. Severe renal dysfunction\n\n         11. Severe bone marrow dysfunction\n\n         12. Severe neurologic or psychotic disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "157", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806753", 
            "org_study_id": "4-2012-0661"
        }, 
        "intervention": [
            {
                "arm_group_label": "midazolam/propofol injection", 
                "description": "In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.\nFirst, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.\nWhen the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).\nIf MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected.", 
                "intervention_name": "Intermittent midazolam/propofol injection controlled by endoscopist", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "propofol infusion", 
                "description": "In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.\nFirst, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.\nThen, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.\nWhen the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.\nIf MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min.", 
                "intervention_name": "Continuous propofol infusion with opioid administration", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Midazolam", 
                "Propofol", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Endoscopic submucosal dissection", 
            "Sedation", 
            "Propofol", 
            "Midazolam"
        ], 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Severance Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Satisfaction of endoscopists", 
            "safety_issue": "Yes", 
            "time_frame": "Within 10 minutes from the end of the endoscopic submucosal dissection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806753"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}